Evidence map›Paper›PMID 40510419›Full record

ArticleFrontiers in pharmacology2025

Therapeutic potential of

Shinn-Zong Lin, Wei-Wen Kuo, Bruce Chi-Kang Tsai, Catherine Reena Paul, Chia-Hua Kuo, Dennis Jine-Yuan Hsieh, Shih-Wen Kao, Pei-Ying Pai, Shan-Jun Chen, Chih-Yang Huang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shinn-Zong LinBioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Wei-Wen KuoDepartment of Biological Science and Technology, College of Life Sciences, China Medical University, Taichung, Taiwan.
Bruce Chi-Kang TsaiCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Catherine Reena PaulCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Chia-Hua KuoLaboratory of Exercise Biochemistry, University of Taipei, Taipei, Taiwan.
Dennis Jine-Yuan HsiehDepartment of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.
Shih-Wen KaoDepartment of Orthopedic Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan.
Pei-Ying PaiSchool of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Shan-Jun ChenHome Run Biotechnology Co., Ltd., Tainan, Taiwan.
Chih-Yang Huang *Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Kuan-Ho Lin *School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic nephropathy (DN), a leading cause of chronic kidney disease and end-stage renal disease, is a serious complication of type 2 diabetes mellitus (T2DM). Current therapies primarily slow disease progression but are unable to reverse kidney damage, highlighting the need for novel therapy to treat DN. Objective: This study evaluated the therapeutic potential of Results: Treatment with the specially cultivated Conclusion: These results suggest that the specially cultivated

Indexed as

Cordyceps militarisdiabetes mellitusdiabetic nephropathyGinkgo biloba seedskidney

Identifiers

PMID40510419
PMCPMC12158992

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.